Tacalyx raises €7.0M Seed round
11 June 2024· Berlin, Germany· health, biotech, oncology, b2b, deep_hardware
The extension funding will be used to advance two novel antibodies to the late preclinical stage and progress several earlier-stage programs targeting tumor-associated carbohydrate antigens (TACAs).
Investors
LeadThuja Capital
Also participating
High-Tech GründerfondsEurazeoKurma PartnersCreathor VenturesCoparionBoehringer Ingelheim Venture FundMax-Planck-Society
About Tacalyx
Stage
Seed
Headquarters
Berlin, Germany
Founded
2019
Team Size
6–20
Sectors
healthbiotechoncologyb2bdeep_hardware